SLPI and bacterial infectious disease: It is unclear what predisposes patients with COPD to secondary bacterial infections, although it has been suggested that observed reductions in levels of the antibacterial peptides secretory leukocyte protease inhibitor (SLPI) and elafin in COPD patients may contribute [113].